AN2 Therapeutics, Inc. Common Stock
N/A
USD
N/A
N/A
...
Chart
Financials
Description
ANTX Company Description
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
ANTX Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view ANTX Smart Score
Score Breakdown
ANTX Company Description
Show More
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. Show Less
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of ANTX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ANTX's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of ANTX in WallStreetBets Daily Discussion
ANTX News
Recent insights relating to ANTX
CNBC Recommendations
Recent picks made for ANTX stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in ANTX
Corporate Flights
Flights by private jets registered to ANTX
Our Analysis